Oral contraceptives (OCs) are used by millions of women and have proven to be very
effective in contraception. To a large extent as a consequence of the cardiovascular side …

An increased risk of venous thrombosis has been demonstrated in women receiving oral
contraceptives (OCs). This risk has been primarily associated with the oestrogen content, but …

Cardiovascular risks have been a concern since combined oral contraceptives (OCs) were
first introduced. In the past four years new, mostly reassuring information on the safety of …

We investigated the effects of ethinylestradiol dose (50, 30 and 20 μg) and progestogen type
[desogestrel (DSG), gestodene (GSD), levonorgestrel (LNG) and norgestimate (NGM)] in …

The use of oral contraceptives (OC) causes disturbances of the procoagulant, anticoagulant
and fibrinolytic pathways of blood coagulation which may contribute to the increased risk of …

Oral contraceptives (OC) are either composed of a combination of an estrogen derivative
(usually ethinly estradiol) and a progestogen, or they contain a progestogen only. OC are …

Concern about the risks of cardiovascular illness in women using combined oral
contraceptives (OC) containing the progestagens desogestrel and gestodene prompted two …

PIP: Recent studies suggesting that oral contraceptives (OCs) containing the progestins
desogestrel and gestodene are associated with a two-fold increased risk of nonfatal venous …

We studied 67 healthy women who were randomly allocated to receive third generation
gestodene (Gynera®) or second generation levonorgestrel (Microgynon 30®) combina tion …

Objective. The scientific debate on oral contraceptives (OCs) and thrombotic diseases
continues unabated. The aim of this survey was to evaluate available scientific data on OCs …